SCHEMBL4405370

SCHEMBL4405370

COc1cc(OC)c(F)c(NCc2cnc(SC)nc2NC2CCCC2)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.40
PDGFRA P16234 3/20 0.40
SELP P16109 4/20 0.39
TYRO3 Q06418 4/20 0.39
HTT P42858 2/20 0.38
AURKA O14965 2/20 0.36
CHEK1 O14757 1/20 0.36
IKBKB O14920 1/20 0.36
PAK4 O96013 1/20 0.36
CHEK2 O96017 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
INSR P06213 1/20 0.36
LCK P06239 1/20 0.36
FGFR1 P11362 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
MAPK1 P28482 1/20 0.36
AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4401606 0.96 HTT (0.39) PDGFRBPDGFRASELPTYRO3HTT
SCHEMBL4410449 0.83 HTT (0.43) HTTMAPK1GSK3BKDM4EBCL6
SCHEMBL4395977 0.83 HTT (0.34) SELPTYRO3HTTAURKACHEK1
SCHEMBL25046162 0.77 MERTK (0.43) SELPTYRO3HTTABL1MEN1
SCHEMBL4395948 0.76 PDGFRB (0.40) PDGFRBPDGFRAAURKAMEN1KMT2A
SCHEMBL4395951 0.76 PDGFRB (0.40) PDGFRBPDGFRAAURKAMEN1KMT2A
SCHEMBL16071413 0.76 HTT (0.45) PDGFRATYRO3HTTCDK2MERTK
SCHEMBL29714339 0.75 KMT2A (0.47) PDGFRBPDGFRASELPTYRO3MEN1
SCHEMBL24496115 0.75 KMT2A (0.47) PDGFRBPDGFRASELPTYRO3MEN1
SCHEMBL18926253 0.75 JAK1 (0.46) PDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 PDGFRB 143/4885PDGFRA 170/4885SELP 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.